share_log

康寧傑瑞製藥-B:2024中期報告

ALPHAMAB-B: 2024 INTERIM REPORT

HKEX ·  Sep 20 04:35

Summary by Moomoo AI

康寧傑瑞制藥-B(ALPHAMAB ONCOLOGY)於2024年發布中期報告,顯示期內收入為人民幣173,561千元,較去年同期增長,但仍錄得期內虧損人民幣44,896千元。報告期間,公司研發開支為人民幣194,531千元,與去年同期相若。公司主要從事腫瘤生物製劑的研發、生產及商業化,並於報告期間無派發股息。截至2024年6月30日,公司流動資產為人民幣1,592,832千元,流動負債為人民幣345,376千元,資產淨值為人民幣1,628,751千元。
康寧傑瑞制藥-B(ALPHAMAB ONCOLOGY)於2024年發布中期報告,顯示期內收入為人民幣173,561千元,較去年同期增長,但仍錄得期內虧損人民幣44,896千元。報告期間,公司研發開支為人民幣194,531千元,與去年同期相若。公司主要從事腫瘤生物製劑的研發、生產及商業化,並於報告期間無派發股息。截至2024年6月30日,公司流動資產為人民幣1,592,832千元,流動負債為人民幣345,376千元,資產淨值為人民幣1,628,751千元。
Alphamab Oncology released its mid-term report in 2024, showing revenue of RMB 173,561 thousand for the period, an increase compared to the same period last year, but still resulting in a loss of RMB 44,896 thousand for the period. During the reporting period, the company's R&D expenses were RMB 194,531 thousand, similar to the same period last year. The company is mainly engaged in the research, development, production, and commercialization of oncology biologics, and did not distribute dividends during the reporting period. As of June 30, 2024, the company's current assets were RMB 1,592,832 thousand, current liabilities were RMB 345,376 thousand, and the net assets were RMB 1,628,751 thousand.
Alphamab Oncology released its mid-term report in 2024, showing revenue of RMB 173,561 thousand for the period, an increase compared to the same period last year, but still resulting in a loss of RMB 44,896 thousand for the period. During the reporting period, the company's R&D expenses were RMB 194,531 thousand, similar to the same period last year. The company is mainly engaged in the research, development, production, and commercialization of oncology biologics, and did not distribute dividends during the reporting period. As of June 30, 2024, the company's current assets were RMB 1,592,832 thousand, current liabilities were RMB 345,376 thousand, and the net assets were RMB 1,628,751 thousand.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more